This study compares the efficacy and safety of acarbose against voglibose in patients with type 2 diabetes inadequately controlled by insulin glargine and/or metformin. Given the increasing prevalence of type 2 diabetes globally, the potential market for effective oral hypoglycemic agents remains substantial. Bayer's positioning with acarbose could enhance its portfolio in diabetes management, particularly in markets where voglibose is a competitor. The results may influence prescribing patterns and market share dynamics, especially in regions where both drugs are available. Diligence should focus on the competitive landscape, particularly the acceptance of acarbose in clinical practice compared to voglibose and other newer agents.